Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Mol Cancer Ther. 2017 Nov 20;17(1):39–49. doi: 10.1158/1535-7163.MCT-17-0574

Figure 5. Therapeutic efficacy of PTC-028 in the orthotopic OV90 model.

Figure 5

(A) OV90 cells were implanted in the bursa of bilateral ovaries in athymic female nude mice. One week later mice were randomized into 3 groups of 7-10 each and treatment initiated. PTC-028 was administered orally at 15 mg/kg twice weekly. Cisplatin at 3 mg/kg/weekly and paclitaxel at 15 mg/kg/weekly were administered by intraperitoneal injections and vehicle control given orally and intraperitoneally. Three weeks after treatment, the mice were euthanized and tumor tissues collected, weighed and processed. Representative images of the tumors within the ovary and after resection from each group are shown. (B) Top panel depicts average and individual tumor weight ± SD from each group. *P<0.05 compared to the control group by a one-way ANOVA. Bottom panel depicts average body weight of the mice after treatment from each group. (C) Immunohistochemical staining of tumor xenografts for BMI-1 (upper panel), Ki67 (middle panel) and TUNEL positivity (lower panel). After quantification fold changes with respect to the control are shown graphically on the right, scale bar represent 50 μm for BMI-1, Ki67 and 10 μm for TUNEL. *P<0.05 compared to the control group by a one-way ANOVA.